Menu

NIH Won’t Use Industry Money for Opioid Research Initiative

The announcement comes after an agency working group recommends against an industry partnership on ethical grounds.

Apr 19, 2018
Shawna Williams

ISTOCK, MITCHELL WESSELLSThe National Institutes of Health (NIH) will exclusively use taxpayer money for a research initiative on the treatment of pain and substance use disorder, STAT News reports. The announced funding is a shift from what had been touted as a potential public-private partnership, with the federal government and drug companies each contributing approximately $200 million to the initiative.

The change comes after an NIH working group recommended last month that only federal funds be used for planned research aimed at alleviating the opioid crisis. The intent is “[t]o mitigate the risk of real or perceived conflict of interest,” the working group noted. The shift away from using private money for the initiative also comes amid controversy over an NIH agency’s courting of industry funders for a proposed study on the health effects of drinking alcohol.

“There’s so much controversy swirling around pharmaceuticals on the opioid issue,” Rep. Tom Cole (R-Okla.), who chairs the House appropriations subcommittee on health, tells STAT, adding that he agrees with NIH’s decision. An NIH spokesperson tells the outlet that the planned research can proceed with only federal funds thanks to budget increases in last month’s omnibus spending bill.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.